Tell Congress: Investigate FDA’s Failure to Examine Claims That Pfizer Falsified Vaccine Trial Data

On Nov. 2, The BMJ published an investigation into the poor research practices at Ventavia, a contract research company that conducted COVID-19 vaccine trials for Pfizer.

According to The BMJ, “speed may have come at the cost of data integrity and patient safety.”

Take action here: Tell Congress to investigate the FDA’s failure to examine claims that Pfizer falsified COVID vaccine trial data.

Brook Jackson, a former Ventavia employee told The BMJ that Ventavia:

“ … falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial. Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding.”

Jackson repeatedly notified Ventavia about her concerns, The BMJ reported.

She also emailed a complaint to the U.S. Food and Drug Administration (FDA). Along with her complaint, Jackson included “dozens of internal company documents, photos, audio recordings and emails.”

The FDA never responded to Jackson, who was fired after her email to the agency.

The FDA’s Vaccines and Related Biological Products Advisory Committee on Oct. 26 granted Emergency Use Authorization of Pfizer’s COVID vaccine for children ages 5 through 11 — nearly a year after Jackson notified the FDA about her concerns.

“VRBPAC committee members have extensive ties with the same drug companies that manufacture the vaccines they vote on,” said Mary Holland, Children’s Health Defense  president and general counsel. “It’s obvious from their voting records that their allegiance is to Pharma and not to the health of our nation’s children.”

Take action here: Tell Congress to investigate the FDA’s failure to examine claims that Pfizer falsified COVID vaccine trial data.

The post Tell Congress: Investigate FDA’s Failure to Examine Claims That Pfizer Falsified Vaccine Trial Data appeared first on Children’s Health Defense.

Share DeepPol
more